Valganciclovir
- TRADE NAME: Valcyte (Roche)
- INDICATIONS: Cytomegalovirus retinitis (CMV) in patients with AIDS, prevention of CMV disease in high-risk transplant patients
- CLASS: Antiviral, Guanine nucleoside analog
- HALF-LIFE: 4 hours (in severe renal impairment up to 68%)
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Abacavir, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Alafenamide, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil, Emtricitabine, Tenofovir Disoproxil
PREGNANCY CATEGORY: N/A
May cause fetal toxicity based on findings in animal studies
Valganciclovir is rapidly converted to ganciclovir in the body.
HEMATOLOGIC TOXICITY, IMPAIRMENT OF FERTILITY, FETAL TOXICITY, MUTAGENESIS AND CARCINOGENESIS
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
OTHER.
Page last updated 08/02/2021
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
